Form 8K Rallybio Corp For: 6 November
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Rallybio Corp (RLYB)
Rallybio Corp stock price live, this page displays NASDAQ RLYB stock exchange data. View the RLYB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Rallybio Corp real time stock price chart below.
What Is the Rallybio Corp Stock Price Today?
The Rallybio Corp stock price today is 0.672.
What Is the Stock Symbol for Rallybio Corp?
The stock symbol for Rallybio Corp is "RLYB."
What Stock Exchange Does Rallybio Corp Trade On?
Rallybio Corp is listed and trades on the NASDAQ stock exchange.
Is Rallybio Corp a Good Stock to Buy?
Determining whether Rallybio Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RLYB quote. (ISIN: US75120L1008)
What Is the Rallybio Corp Stock Price Today?
The Rallybio Corp stock price today is 0.672.
What Is the Stock Symbol for Rallybio Corp?
The stock symbol for Rallybio Corp is "RLYB."
What Stock Exchange Does Rallybio Corp Trade On?
Rallybio Corp is listed and trades on the NASDAQ stock exchange.
Is Rallybio Corp a Good Stock to Buy?
Determining whether Rallybio Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RLYB quote. (ISIN: US75120L1008)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.584
0.725
52 wk Range
0.220
0.950
RLYB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.5840.725
52 wk Range
0.2200.950
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RLYB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
1.000
Upside
+48.81%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Rallybio Corp Company Profile
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Rallybio Corp SWOT Analysis
C5 Inhibitor Pivot | Rallybio shifts focus to RLYB116, a promising C5 inhibitor, following discontinuation of FNAIT program. Phase 1 trial data expected in H2 2025. |
Pipeline Progress | Explore Rallybio's collaboration with Recursion on REV102 for hypophosphatasia and the potential for RLYB116 in antiphospholipid syndrome. |
Financial Resilience | Delve into Rallybio's strong cash position, extending runway into 2027, and its recent financial performance exceeding analyst expectations. |
Market Outlook | Analyst price targets range from $5 to $7, with mixed ratings. Learn how upcoming trial results could reshape investor sentiment and valuation. |
Compare RLYB to Peers and Sector
Metrics to compare | RLYB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRLYBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.0x | −3.9x | −0.6x | |
PEG Ratio | −0.03 | 0.16 | 0.00 | |
Price/Book | 0.5x | 1.6x | 2.6x | |
Price / LTM Sales | 42.1x | 349.5x | 3.4x | |
Upside (Analyst Target) | 48.8% | 131.1% | 42.0% | |
Fair Value Upside | Unlock | −9.3% | 5.0% | Unlock |
Analyst Ratings
1 Buy
3 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 1.000
(+48.81% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
0.36 / -0.20
Revenue / Forecast
200.00K / --
People Also Watch
FAQ
What Is the Rallybio (RLYB) Stock Price Today?
The Rallybio stock price today is 0.672
What Stock Exchange Does Rallybio Trade On?
Rallybio is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Rallybio?
The stock symbol for Rallybio is "RLYB."
What Is the Rallybio Market Cap?
As of today, Rallybio market cap is 28.37M.
What Is Rallybio's Earnings Per Share (TTM)?
The Rallybio EPS (TTM) is -0.32.
When Is the Next Rallybio Earnings Date?
Rallybio will release its next earnings report on Mar 17, 2026.
From a Technical Analysis Perspective, Is RLYB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Rallybio Stock Split?
Rallybio has split 0 times.
How Many Employees Does Rallybio Have?
Rallybio has 15 employees.
What is the current trading status of Rallybio (RLYB)?
As of Jan 24, 2026, Rallybio (RLYB) is trading at a price of 0.672, with a previous close of 0.673. The stock has fluctuated within a day range of 0.584 to 0.725, while its 52-week range spans from 0.220 to 0.950.
What Is Rallybio (RLYB) Price Target According to Analysts?
The average 12-month price target for Rallybio is USD1.000, with a high estimate of USD1 and a low estimate of USD1. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +48.81% Upside potential.
What Is the RLYB Premarket Price?
RLYB's last pre-market stock price is 0.719. The pre-market share volume is 290.000, and the stock has decreased by 0.046, or 6.840%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.